Clinical trials of ACT001, a New Drug Candidate originally developed


    Prof. Yue Chen invented an anti-glioblastoma drug candidate ACT001, which can penetrate the blood-brain barrier and selectively kill cancer stem cells. Ten clinical trials have been approved in China, America and Australia. At present, phase I clinical trials in China and Australia have been completed, and six phase 1b / 2a and phase II clinical trials are ongoing. Also, it was designated as orphan drug by FDA and EMA. In 2018, part of the outcome of phase I was presented in ASCO meeting.